Literature DB >> 22929991

Sarcopenia: pharmacology of today and tomorrow.

Marco Brotto1, Eduardo L Abreu.   

Abstract

Sarcopenia remains largely undiagnosed and undertreated because of the lack of a universally accepted definition, effective ways to measure it, and identification of the outcomes that should guide treatment efficacy. An ever-growing number of clinicians and researchers along with funding and regulatory agencies have gradually recognized that sarcopenia is a human condition that requires both prevention and treatment. In this article, we review sarcopenia and its common and less known pharmacological treatments, attempt to define sarcopenia in its broader context, and present some new ideas for potential future treatment for this devastating condition.

Entities:  

Mesh:

Year:  2012        PMID: 22929991      PMCID: PMC3500539          DOI: 10.1124/jpet.112.191759

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  72 in total

Review 1.  Skeletal muscle damage with exercise and aging.

Authors:  Graeme L Close; Anna Kayani; Aphrodite Vasilaki; Anne McArdle
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

2.  Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract.

Authors:  A Cole-Strauss; H Gamper; W K Holloman; M Muñoz; N Cheng; E B Kmiec
Journal:  Nucleic Acids Res       Date:  1999-03-01       Impact factor: 16.971

Review 3.  Sarcopenia: assessment of muscle mass.

Authors:  H Lukaski
Journal:  J Nutr       Date:  1997-05       Impact factor: 4.798

Review 4.  Consequences of sarcopenia.

Authors:  Marjolein Visser; Laura A Schaap
Journal:  Clin Geriatr Med       Date:  2011-05-14       Impact factor: 3.076

5.  Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat.

Authors:  Iman Momken; Laurence Stevens; Audrey Bergouignan; Dominique Desplanches; Floriane Rudwill; Isabelle Chery; Alexandre Zahariev; Sandrine Zahn; T Peter Stein; Jean Louis Sebedio; Estelle Pujos-Guillot; Maurice Falempin; Chantal Simon; Véronique Coxam; Tany Andrianjafiniony; Guillemette Gauquelin-Koch; Florence Picquet; Stéphane Blanc
Journal:  FASEB J       Date:  2011-06-29       Impact factor: 5.191

Review 6.  Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition?

Authors:  Deepa Sumukadas; Allan D Struthers; Marion E T McMurdo
Journal:  Gerontology       Date:  2006       Impact factor: 5.140

7.  The healthcare costs of sarcopenia in the United States.

Authors:  Ian Janssen; Donald S Shepard; Peter T Katzmarzyk; Ronenn Roubenoff
Journal:  J Am Geriatr Soc       Date:  2004-01       Impact factor: 5.562

8.  Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.

Authors:  Blake C Beehler; Paul G Sleph; Latifa Benmassaoud; Gary J Grover
Journal:  Exp Biol Med (Maywood)       Date:  2006-03

9.  Store-operated Ca(2+) entry (SOCE) contributes to normal skeletal muscle contractility in young but not in aged skeletal muscle.

Authors:  Angela M Thornton; Xiaoli Zhao; Noah Weisleder; Leticia S Brotto; Sylvain Bougoin; Thomas M Nosek; Michael Reid; Brian Hardin; Zui Pan; Jianjie Ma; Jerome Parness; Marco Brotto
Journal:  Aging (Albany NY)       Date:  2011-06       Impact factor: 5.682

10.  The bone-muscle relationship in men and women.

Authors:  Thomas F Lang
Journal:  J Osteoporos       Date:  2011-10-05
View more
  29 in total

1.  Muscle and Bone Mass Loss in the Elderly Population: Advances in diagnosis and treatment.

Authors:  Carlos J Padilla Colón; Irma L Molina-Vicenty; María Frontera-Rodríguez; Alejandra García-Ferré; Bernabejoel Ponce Rivera; Gerardo Cintrón-Vélez; Sebastián Frontera-Rodríguez
Journal:  J Biomed (Syd)       Date:  2018

2.  Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.

Authors:  M Invernizzi; S Carda; M Rizzi; E Grana; D F Squarzanti; C Cisari; C Molinari; F Renò
Journal:  Spinal Cord       Date:  2015-04-21       Impact factor: 2.772

Review 3.  Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment.

Authors:  Maren S Fragala; Anne M Kenny; George A Kuchel
Journal:  Sports Med       Date:  2015-05       Impact factor: 11.136

4.  METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-κB signaling pathway.

Authors:  Jian Huang; Yi-Hsiang Hsu; Maxrco Brotto; David Karasik; Chenglin Mo; Eduardo Abreu; Douglas P Kiel; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

Review 5.  Selecting Potential Pharmacological Interventions in Sarcopenia.

Authors:  Amanda J Kilsby; Avan A Sayer; Miles D Witham
Journal:  Drugs Aging       Date:  2017-04       Impact factor: 3.923

6.  Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training.

Authors:  Mohammad Alturki; Keliane Liberman; Andreas Delaere; Liza De Dobbeleer; Veerle Knoop; Tony Mets; Siddhartha Lieten; Bert Bravenboer; Ingo Beyer; Ivan Bautmans
Journal:  Drugs Aging       Date:  2021-02-05       Impact factor: 3.923

7.  Lessons from the FNIH-NIA-FDA sarcopenia consensus summit.

Authors:  Marco Brotto
Journal:  IBMS Bonekey       Date:  2012-11-14

8.  Physiological role of Kvβ2 (AKR6) in murine skeletal muscle growth and regulation.

Authors:  K C Chapalamadugu; J Tur; S L Badole; R C Kukreja; M Brotto; S M Tipparaju
Journal:  Acta Physiol (Oxf)       Date:  2018-06-06       Impact factor: 6.311

9.  Abnormal myofiber morphology and limb dysfunction in claudication.

Authors:  Panagiotis Koutakis; Sara A Myers; Kim Cluff; Duy M Ha; Gleb Haynatzki; Rodney D McComb; Koji Uchida; Dimitrios Miserlis; Evlampia Papoutsi; Jason M Johanning; George P Casale; Iraklis I Pipinos
Journal:  J Surg Res       Date:  2015-02-13       Impact factor: 2.192

10.  Identifying Sarcopenia in Female Long-Term Care Residents: A Comparison of Current Guidelines.

Authors:  Mary P Kotlarczyk; Subashan Perera; David A Nace; Neil M Resnick; Susan L Greenspan
Journal:  J Am Geriatr Soc       Date:  2017-11-20       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.